{
  "guideline": {
    "id": "PA166262341",
    "name": "Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1",
    "objCls": "Guideline Annotation",
    "source": "CPIC",
    "version": 6,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262341",
    "relatedChemicals": [
      {
        "id": "PA449688",
        "name": "fluvastatin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      },
      {
        "id": "PA134865839",
        "name": "solute carrier organic anion transporter family member 1B1",
        "symbol": "SLCO1B1"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166297923",
      "name": "Recommendation PA166297923",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060525,
        "html": "<p>Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297910",
      "name": "Recommendation PA166297910",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060512,
        "html": "<p>Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297949",
      "name": "Recommendation PA166297949",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060551,
        "html": "<p>Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297936",
      "name": "Recommendation PA166297936",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060538,
        "html": "<p>Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297914",
      "name": "Recommendation PA166297914",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060516,
        "html": "<p>Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297905",
      "name": "Recommendation PA166297905",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060507,
        "html": "<p>Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297919",
      "name": "Recommendation PA166297919",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060521,
        "html": "<p>Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297950",
      "name": "Recommendation PA166297950",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060552,
        "html": "<p>Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297906",
      "name": "Recommendation PA166297906",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060508,
        "html": "<p>Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297941",
      "name": "Recommendation PA166297941",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060543,
        "html": "<p>Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297945",
      "name": "Recommendation PA166297945",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060547,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297932",
      "name": "Recommendation PA166297932",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060534,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297911",
      "name": "Recommendation PA166297911",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060513,
        "html": "<p>Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297946",
      "name": "Recommendation PA166297946",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060548,
        "html": "<p>Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day. CYP2C9 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297937",
      "name": "Recommendation PA166297937",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060539,
        "html": "<p>Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297924",
      "name": "Recommendation PA166297924",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060526,
        "html": "<p>Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297915",
      "name": "Recommendation PA166297915",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060517,
        "html": "<p>Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297888",
      "name": "Recommendation PA166297888",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060490,
        "html": "<p>Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal exposure.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297928",
      "name": "Recommendation PA166297928",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060530,
        "html": "<p>Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal exposure.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166297907",
      "name": "Recommendation PA166297907",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060509,
        "html": "<p>Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297951",
      "name": "Recommendation PA166297951",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060553,
        "html": "<p>Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297942",
      "name": "Recommendation PA166297942",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060544,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166297933",
      "name": "Recommendation PA166297933",
      "population": "general",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060535,
        "html": "<p>n/a</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297920",
      "name": "Recommendation PA166297920",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060522,
        "html": "<p>Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297947",
      "name": "Recommendation PA166297947",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060549,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166297934",
      "name": "Recommendation PA166297934",
      "population": "general",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060536,
        "html": "<p>n/a</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297925",
      "name": "Recommendation PA166297925",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060527,
        "html": "<p>Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297912",
      "name": "Recommendation PA166297912",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060514,
        "html": "<p>Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297929",
      "name": "Recommendation PA166297929",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060531,
        "html": "<p>Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal exposure.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166297916",
      "name": "Recommendation PA166297916",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060518,
        "html": "<p>Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297952",
      "name": "Recommendation PA166297952",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060554,
        "html": "<p>Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297908",
      "name": "Recommendation PA166297908",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060510,
        "html": "<p>Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297943",
      "name": "Recommendation PA166297943",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060545,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297930",
      "name": "Recommendation PA166297930",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060532,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166297921",
      "name": "Recommendation PA166297921",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060523,
        "html": "<p>Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297935",
      "name": "Recommendation PA166297935",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060537,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297922",
      "name": "Recommendation PA166297922",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060524,
        "html": "<p>Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297913",
      "name": "Recommendation PA166297913",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060515,
        "html": "<p>Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297939",
      "name": "Recommendation PA166297939",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060541,
        "html": "<p>Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297926",
      "name": "Recommendation PA166297926",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060528,
        "html": "<p>Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal exposure.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297917",
      "name": "Recommendation PA166297917",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060519,
        "html": "<p>Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal exposure.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297904",
      "name": "Recommendation PA166297904",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060506,
        "html": "<p>Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297918",
      "name": "Recommendation PA166297918",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060520,
        "html": "<p>Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297909",
      "name": "Recommendation PA166297909",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060511,
        "html": "<p>Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal exposure.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297940",
      "name": "Recommendation PA166297940",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060542,
        "html": "<p>Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose &gt;40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297878",
      "name": "Recommendation PA166297878",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060480,
        "html": "<p>Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal exposure.",
        "SLCO1B1: Typical myopathy risk and statin exposure."
      ],
      "lookupKey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297931",
      "name": "Recommendation PA166297931",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060533,
        "html": "<p>Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      ],
      "lookupKey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166297944",
      "name": "Recommendation PA166297944",
      "population": "general",
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449688",
          "name": "fluvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060546,
        "html": "<p>n/a</p>\n"
      },
      "implications": [
        "CYP2C9: n/a",
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "35152405",
      "title": "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.",
      "authors": [
        "Cooper-DeHoff Rhonda M",
        "Niemi Mikko",
        "Ramsey Laura B",
        "Luzum Jasmine A",
        "Tarkiainen E Katriina",
        "Straka Robert J",
        "Gong Li",
        "Tuteja Sony",
        "Wilke Russell A",
        "Wadelius Mia",
        "Larson Eric A",
        "Roden Dan M",
        "Klein Teri E",
        "Yee Sook Wah",
        "Krauss Ronald M",
        "Turner Richard M",
        "Palaniappan Latha",
        "Gaedigk Andrea",
        "Giacomini Kathleen M",
        "Caudle Kelly E",
        "Voora Deepak"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072"
    }
  ],
  "version": "2024-03-08-14-34"
}